Radionuklidbehandling af neuroendokrine tumorer

Research output: Contribution to journalJournal articleResearchpeer-review

Jann Mortensen, Peter Oturai, Liselotte Højgaard, Ulrich Knigge, Carsten Palnaes Hansen, Lars Martiný, Palle Rasmussen, Andreas Kjær, Peter Sandor Oturai

Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.
Original languageDanish
JournalUgeskrift for Laeger
Issue number43
Pages (from-to)2950-3
Number of pages4
Publication statusPublished - 25 Oct 2010

ID: 34045116